Determining the effective sample size of a parametric prior
about
Summarizing historical information on controls in clinical trialsAdaptive adjustment of the randomization ratio using historical control data.Use of historical control data for assessing treatment effects in clinical trials.Bayesian inference from count data using discrete uniform priors.Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis.Using phase II data for the analysis of phase III studies: An application in rare diseases.Covariate-adjusted borrowing of historical control data in randomized clinical trials.Interplay of priors and skeletons in two-stage continual reassessment method.Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free SurvivalComputing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression MetamodelingBayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.A simulation study of methods for selecting subgroup-specific doses in phase 1 trials.Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials.Simple Penalties on Maximum-Likelihood Estimates of Genetic Parameters to Reduce Sampling Variation.Effect of design specifications in dose-finding trials for combination therapies in oncology.A Bayesian test for Hardy-Weinberg equilibrium of biallelic X-chromosomal markers.Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancerBayesian methods for the design and interpretation of clinical trials in very rare diseases.Prior Effective Sample Size in Conditionally Independent Hierarchical Models.Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics.Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome.Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding.Bayesian Phase II optimization for time-to-event data based on historical information.Dynamic borrowing through empirical power priors that control type I error.Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test.Bayesian hierarchical modeling based on multisource exchangeability.Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study.Robust meta-analytic-predictive priors in clinical trials with historical control information.Comparing definitions of spatial relations for the analysis of geographic disparities in mortality within a Bayesian mixed-effects framework.Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPD.Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes.
P2860
Q29397593-E535B934-5DB1-41C2-B3A7-08E07B728CFCQ30629562-3B0AC915-D4DF-4A43-BB1D-60DAB3895B5BQ30659217-0FC64263-7DC3-43E6-B2FA-B6C30786066EQ30675929-D420C279-88E3-445B-A2A6-A8B25C4CC5FFQ35590334-8FEF3A25-7130-41E6-8E6F-69B29F5E6C41Q36280637-ABBB6D77-A118-4C87-888C-00C79619C564Q36339501-04120794-D0ED-4126-8BD9-6AC41CAEE62CQ36385882-913C445B-D947-487A-B490-401B3A5475C2Q36513919-EC9B3612-CAC4-40D6-B1A0-0BB18EDD2F10Q36734048-3B796FB2-476B-46E9-954E-BB314F540998Q37163118-57E9B7F6-63F1-433C-B56A-FB08C329716BQ37841138-E36BE142-B869-4A00-8AB4-2B23FB179FB0Q38735192-E795518E-ABA7-4941-B755-2025F0BA102CQ38816971-8B3FF927-5995-43BC-BC78-744CF7B9147BQ39006115-82E2FC8D-B28E-4A35-8C2D-933D00F25899Q39321056-7F38E1B8-9929-44B2-9D20-67A0E3322BD7Q39429559-C3CCDABE-4DC6-4B96-B523-BDE60DF1CF22Q39673649-28B1E615-9124-43F3-88F6-6A6D57592044Q40616106-75F0A9FB-5AA3-4541-A7A8-30CC573FC970Q41643181-DE0E8CA9-DC70-4591-B075-B333E446FCABQ41706478-45709ECB-A9E7-4CB1-AE0A-C67C785FAC11Q41908823-03FFE11C-3861-401E-A606-198E5E757251Q42007972-2BD97286-F771-473D-9F6F-1D4369A68809Q42700008-E35CC935-592A-4838-92AD-987C3EA1A431Q42970340-8FAC15BA-BE1B-4806-BB0E-013BEBB48352Q43002849-5BBA5078-6BDE-44F4-AD83-4A484D30958FQ47238385-5656610D-7B17-4514-A984-0D9E9223D8E4Q47329719-4E444AC0-AEC6-4671-835E-1D8571AA510CQ47620106-0BC0CEB7-696F-4AE1-BBBC-D69C9847F7D9Q47786318-B2DB2F17-9C6E-4383-A67F-4A77D11DBF0CQ47793193-FDD8FB66-6F04-48B3-AF96-7E10FD2A6FC7Q51018509-C658BE9D-711E-41A8-94C9-8D73F3C1FE83Q51166767-E34559FF-744C-4B9F-BDA8-B02CC47632B6Q51278385-57695F50-C79F-49EA-AC45-2D06344D117FQ51578084-B7B48782-4123-4453-B919-71F6A80E9A45Q52709604-6C97C633-E0F9-4C19-80C4-D359FBB2DFBC
P2860
Determining the effective sample size of a parametric prior
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Determining the effective sample size of a parametric prior
@en
type
label
Determining the effective sample size of a parametric prior
@en
prefLabel
Determining the effective sample size of a parametric prior
@en
P2093
P2860
P1433
P1476
Determining the effective sample size of a parametric prior
@en
P2093
Peter F Thall
Peter Müller
Satoshi Morita
P2860
P304
P356
10.1111/J.1541-0420.2007.00888.X
P407
P577
2007-08-30T00:00:00Z